Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Clown-Free Zone... sorry, no clowns allowed -- Ignore unavailable to you. Want to Upgrade?

To: Ilaine who wrote (34352)	11/6/2000 7:04:41 PM
From: NOW	Read Replies (1) \| Respond to of 436258

i am glad your experience is a good one. The jury is however still out on the long term safety and cost-benefit of these drugs. I quote from a recent summary article: Despite the enthusiasm for these promising new NSAIDs, some questions remain regarding their highly selective inhibition of COX-2. First, COX-2deficient mice were found to have defects in renal function, female reproductive physiology, and regulation of bone absorption. [28] Two studies found that selective COX-2 inhibitors significantly delayed gastric ulcer healing in rodents. [47] [54] Lastly, COX-2 might generate endogenous prostanoids that are biologically important. In a rat pleurisy model, Gilroy et al showed that selective COX-2 inhibition reduced carrageenin-induced inflammation after 2 hours but significantly exacerbated inflammation after 48 hours. [15] They concluded that COX-2 may be proinflammatory during the early phase of inflammation but may possess anti-inflammatory properties later. McAdam et al reported that celecoxib, but not ibuprofen, reduced the urinary excretion of prostacyclin in healthy subjects and speculated that long-term therapy with COX-2 inhibitors might increase the rate of thrombotic events. [42] The results of these studies indicate that, although the highly selective COX-2 inhibitors offer considerable promise in the treatment of inflammatory arthritides, careful surveillance is needed to determine ultimately their safety and benefit.